



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARK  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
--------------------	-------------	-----------------------	---------------------

9/K24222

EXAMINER
----------

ART UNIT	PAPER NUMBER
----------	--------------

1615

11

DATE MAILED:

INTERVIEW SUMMARY

All participants (applicant, applicant's representative, PTO personnel):

(1) G. S. K. HORT (3) Laura Carruzzi

(2) Anthony Insogna (4) BRIAN REMI

Date of Interview 1-30-03 Dr. RODRIGUEZ

Type: ☐ Telephonic ☐ Televideo Conference ☒ Personal (copy is given to ☐ applicant ☐ applicant's representative).

Exhibit shown or demonstration conducted: ☒ Yes ☐ No If yes, brief description: video

Agreement ☐ was reached. ☒ was not reached.

Claim(s) discussed: claim on record & proposed claim

Identification of prior art discussed: E1

Description of the general nature of what was agreed to if an agreement was reached, or any other comments:

The importance of sizes of the liposomes with a specific percentage of particles falling within one SD of the mean was discussed. The examiner suggested the deletion of "preventing" and "managing" in the proposed claims. Proposed claims C & D might be introduced in claim A. The examiner also suggested defining "vascular disease" and recite "empty" instead of "not bound to drug". A careful review of the amendment will be made and the @

(A fuller description, if necessary, and a copy of the amendments, if available, which the examiner agreed would render the claims allowable must be attached. Also, where no copy of the amendments which would render the claims allowable is available, a summary thereof must be attached.)

☐ It is not necessary for applicant to provide a separate record of the substance of the interview.

Unless the paragraph above has been checked to indicate to the contrary. A FORMAL WRITTEN REPLY TO THE LAST OFFICE ACTION IS NOT WAIVED AND MUST INCLUDE THE SUBSTANCE OF THE INTERVIEW. (See MPEP Section 713.04). If a reply to the last Office action has already been filed, APPLICANT IS GIVEN ONE MONTH FROM THIS INTERVIEW DATE TO FILE A STATEMENT OF THE SUBSTANCE OF THE INTERVIEW.

Examiner Note: You must sign this form unless it is an attachment to another form.

allowability of the claims will be determined

Golamudi S. Kishore, PhD  
Primary Examiner  
Group 1600

## PROPOSED CLAIMS FOR 09/924,222

A. A method for preventing, treating, or managing a vascular disease or condition in a human comprising administering to a human in need thereof a pharmaceutically acceptable and a therapeutically effective amount of unilamellar phospholipid liposomes which are effective in promoting cholesterol mobilization while controlling or preventing an increase in LDL or esterified cholesterol levels.

B. A method for preventing, treating, or managing a vascular disease or condition in a human comprising administering to a human in need thereof a pharmaceutically acceptable and a therapeutically effective amount of unilamellar phospholipid liposomes having a mean diameter of 100 nm or greater.

C. A method for preventing, treating, or managing a vascular disease or condition in a human comprising administering to a human in need thereof pharmaceutically acceptable and therapeutically effective amount of unilamellar phospholipid liposomes having a mean diameter of 125 nm wherein 68% of the particles are within one standard deviation from the mean.

D. The method of A, B or C wherein the liposomes are not bound to drug.

- Mathematical method SD - +

